Présentation de l'entreprise
InflaRx N.V. operates as a clinical-stage biopharmaceutical entity dedicated to discovering and developing inhibitors that utilize C5a technology for treating autoimmune and various other inflammatory diseases in both Germany and the United States. The company functions within the Healthcare sector, specifically the Biotechnology industry, which characterizes its business model as high-risk, high-research-intensive focused on therapeutic innovation rather than established consumer goods. This operational scale is reflected in a market capitalization of $68.68M, an annual revenue of $29,331, and an employee base of 65 individuals. These valuation and revenue figures indicate that the company remains a micro-cap entity with minimal commercial traction, suggesting that its current financial position is heavily reliant on capital deployment for research and development rather than significant revenue generation.
Santé financière
The financial statements for InflaRx N.V. report a trailing twelve-month revenue of $29,331, a net income of $-45,633,780, and an EBITDA of $-48,198,212, highlighting a substantial disparity between top-line activity and bottom-line profitability. The massive gap between the negligible revenue of $29,331 and the negative net income of $-45,633,780 reveals an extremely aggressive cost structure where operating expenses far exceed any generated income, a typical characteristic of early-stage clinical development. The company reports a free cash flow of $-14,833,020, which indicates a continuous cash burn rate that necessitates external financing to sustain operations and fund clinical trials. Margin analysis presents a complex picture with a gross margin of 0.0%, a profit margin of 0.0%, and an operating margin of 37898.3%, where the latter figure is mathematically anomalous given the negative net income and suggests significant non-operating losses or accounting adjustments that distort standard profitability metrics. On the balance sheet, the company holds $46.46M in cash against $897,916 in debt, resulting in a debt-to-equity ratio of 2.16, which implies a leveraged position relative to equity despite the low absolute debt level. The current ratio stands at 4.13, indicating strong short-term liquidity and the ability to cover current liabilities with current assets, providing a buffer for operational runway. Furthermore, the return on equity is -88.6% and the return on assets is -46.0%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently due to the absence of positive earnings.
Évaluation de la valorisation
Valuation multiples for InflaRx N.V. are distorted by its lack of profitability, with a P/E ratio (TTM) listed as N/A and a forward P/E of -1.26, implying that the market is pricing the stock based on future earnings expectations that are not yet realized. The price-to-book ratio is 1.43, indicating that the market values the company at a premium of 43% over its book value, which may reflect potential in the C5a technology platform despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 2341.49 and an EV/EBITDA of -0.48 suggest an extremely high valuation relative to sales, while the negative EV/EBITDA confirms the company is not yet generating positive earnings before interest, taxes, depreciation, and amortization. The stock has a 52-week high of $1.94 and a 52-week low of $0.71, and without a specific current price provided in the facts, the valuation context remains strictly defined by this trading range where the market cap of $68.68M fluctuates within these bounds. The beta is 1.51, meaning the stock's price volatility is 51% higher than the broader market, reflecting the inherent risk associated with clinical-stage biotechnology assets.
Growth & Income
Growth metrics for InflaRx N.V. are unavailable for trailing twelve-month periods, with revenue growth (YoY) and earnings growth (YoY) both listed as N/A, preventing any definitive statement on whether earnings are growing faster or slower than revenue at this stage. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all earnings to reinvest into research, development, and clinical progress rather than distributing income to shareholders. The overall growth and income profile is defined by a complete reliance on capital preservation and strategic reinvestment, as evidenced by the zero dividend yield and the absence of positive earnings growth data. This profile underscores a strategy prioritizing long-term therapeutic discovery over short-term income generation or shareholder returns.